Thiotepa medac: Uses, Dosage & Side Effects
Alkylating chemotherapy agent used as part of conditioning regimens before hematopoietic stem cell transplantation (HSCT) in adults and children, and for selected solid tumors
Thiotepa medac (active substance: thiotepa) is a powerful alkylating chemotherapy agent belonging to the ethyleneimine group of cytotoxic drugs. It is supplied as a 15 mg powder for concentrate for solution for infusion and is administered intravenously in specialized transplant and oncology centers. Thiotepa works by forming irreversible cross-links in cellular DNA, which halts the replication of rapidly dividing cells and ultimately kills them. Its most important modern use is as part of high-dose conditioning regimens before autologous and allogeneic hematopoietic stem cell transplantation (HSCT) in adult and pediatric patients with hematological malignancies and certain solid tumors, including lymphoma, acute leukemia, multiple myeloma, neuroblastoma, medulloblastoma, germ cell tumors, and thalassemia. Because thiotepa crosses the blood-brain barrier, it is particularly valuable when there is a risk of central nervous system involvement. Thiotepa medac requires a prescription and must be given only by healthcare professionals experienced in cytotoxic chemotherapy and stem cell transplantation.
Quick Facts: Thiotepa medac
Key Takeaways
- Thiotepa medac (thiotepa) is a polyfunctional alkylating cytotoxic drug that forms DNA cross-links; it is one of the oldest chemotherapy agents in clinical use, first introduced in the late 1950s and still considered essential in modern transplant medicine.
- Its main use today is as part of high-dose conditioning chemotherapy before autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in adults and children with lymphomas, leukemias, multiple myeloma, neuroblastoma, medulloblastoma, germ cell tumors, and inherited hematological diseases such as beta-thalassemia.
- Thiotepa penetrates the blood-brain barrier and reaches therapeutic concentrations in the cerebrospinal fluid, making it particularly useful for cancers at risk of central nervous system involvement such as primary CNS lymphoma and pediatric brain tumors.
- Almost all patients experience profound bone marrow suppression; serious risks include hepatic veno-occlusive disease (VOD/SOS), severe mucositis, infections, fertility loss, and increased long-term risk of secondary malignancies, requiring treatment only in highly specialized transplant centers.
- Thiotepa is teratogenic and mutagenic – it must not be used during pregnancy or breastfeeding; both male and female patients require effective contraception and should discuss fertility preservation before treatment begins.
What Is Thiotepa medac and What Is It Used For?
The active substance in Thiotepa medac is thiotepa, chemically known as N,N’,N’’-triethylenethiophosphoramide or TESPA. Thiotepa belongs to the class of cytotoxic drugs called alkylating agents, and more specifically to the ethyleneimine (aziridine) subgroup. Alkylating agents are among the oldest and most thoroughly studied chemotherapy drugs, and thiotepa itself has been used in clinical oncology since the late 1950s. Despite its long history, thiotepa retains an essential role in modern hematology and oncology, particularly because of its unique ability to combine strong myeloablative activity with broad antitumor efficacy and good penetration into the central nervous system.
Mechanistically, thiotepa is a pro-drug that becomes pharmacologically active after absorption and metabolism. It carries three chemically identical aziridine (ethyleneimine) rings attached to a central thiophosphoramide. Under physiological conditions, and particularly after enzymatic activation by hepatic cytochrome P450 enzymes (primarily CYP2B6 and CYP3A4), these aziridine rings open to form highly reactive electrophilic carbonium ions. These reactive species readily alkylate nucleophilic sites in DNA, most notably the N7 position of guanine, creating covalent bonds between the drug and DNA nucleotides. Because thiotepa is polyfunctional (possessing three reactive groups), a single thiotepa molecule can cross-link two DNA strands or two positions on the same strand. These inter- and intra-strand DNA cross-links block DNA replication, impair transcription, and trigger programmed cell death (apoptosis).
Thiotepa is active against a wide range of cancer cell types because alkylation damage is not cell-cycle specific, although cells in the process of DNA replication are most vulnerable. In addition to its direct cytotoxic effect, thiotepa and its principal active metabolite TEPA (triethylenephosphoramide) produce profound and long-lasting bone marrow suppression. This myeloablative property is exactly what is needed when preparing a patient to receive a bone marrow or stem cell transplant: the recipient’s own diseased or cancerous marrow must be destroyed to create “space” for the donor stem cells to engraft and to eliminate residual malignant cells.
Another distinctive pharmacological feature of thiotepa is its excellent penetration through the blood-brain barrier. Cerebrospinal fluid concentrations of thiotepa can approach plasma concentrations – an unusual property for chemotherapy agents, most of which are excluded from the central nervous system. This makes thiotepa particularly useful in cancers that involve, or are at risk of involving, the brain and meninges.
Hematopoietic Stem Cell Transplantation (HSCT) Conditioning
The principal indication of Thiotepa medac in modern medicine is as part of high-dose conditioning chemotherapy before autologous or allogeneic hematopoietic stem cell transplantation. The goal of conditioning is twofold: (1) to destroy the recipient’s bone marrow and residual malignant cells, and (2) in allogeneic transplant, to suppress the recipient’s immune system sufficiently to allow donor stem cells to engraft without rejection.
Thiotepa is typically given in combination with other conditioning agents such as busulfan, fludarabine, cyclophosphamide, melphalan, carboplatin, or etoposide, in regimens often referred to as TBF (thiotepa-busulfan-fludarabine), TBC (thiotepa-busulfan-cyclophosphamide), or BEAM-variant regimens. According to the European Medicines Agency label, Thiotepa medac is indicated in combination with other chemotherapy medicinal products:
- With or without total body irradiation (TBI), as conditioning treatment before allogeneic or autologous hematopoietic progenitor cell transplantation (HPCT) in hematological diseases in adult and pediatric patients;
- When high-dose chemotherapy with HPCT support is appropriate for the treatment of solid tumors in adult and pediatric patients.
In adult practice, thiotepa-based conditioning is widely used for lymphomas (including primary central nervous system lymphoma, where thiotepa is a cornerstone), multiple myeloma, acute myeloid leukemia, and selected solid tumors. In pediatric practice, thiotepa is a backbone drug in the treatment of high-risk neuroblastoma, medulloblastoma and other embryonal brain tumors, relapsed germ cell tumors, and in hemoglobinopathies such as beta-thalassemia major and sickle cell disease where allogeneic stem cell transplant is curative.
Primary Central Nervous System Lymphoma (PCNSL)
Primary central nervous system lymphoma is an aggressive extranodal non-Hodgkin lymphoma confined to the brain, spinal cord, eyes, or leptomeninges. Because most chemotherapy drugs cannot cross the blood-brain barrier in therapeutic concentrations, treatment of PCNSL has historically been challenging. Thiotepa’s ability to penetrate the central nervous system makes it a cornerstone of modern PCNSL therapy. The IELSG32 and MATRix trials established thiotepa-containing high-dose chemotherapy followed by autologous stem cell transplantation as a standard of care consolidation strategy in younger, fit patients, yielding significantly improved progression-free and overall survival.
Other Historical and Specialized Uses
At lower, non-myeloablative doses, thiotepa has a long history of use in other tumors, although in many of these indications it has been superseded by newer agents:
- Adenocarcinoma of the breast and ovary – used systemically or intracavitarily in selected patients.
- Non-invasive (superficial) bladder cancer – instilled directly into the bladder (intravesical thiotepa) for prophylaxis and treatment of superficial transitional cell carcinoma, particularly after transurethral resection of bladder tumors.
- Malignant effusions – intracavitary instillation of thiotepa into the pleural, peritoneal, or pericardial cavity has been used historically to control neoplastic effusions.
- Intrathecal use – in selected specialized centers thiotepa has been given intrathecally for meningeal leukemia or lymphoma, although this use is uncommon today.
Despite the availability of many newer targeted therapies, thiotepa retains a unique and essential role in HSCT conditioning because of its combination of properties: potent myeloablation, broad antitumor activity, excellent CNS penetration, and the ability to be combined synergistically with other conditioning drugs. Current European and American transplant guidelines (EBMT, ASTCT) continue to recommend thiotepa-based regimens as standards of care across multiple indications in both pediatric and adult practice.
What Should You Know Before Receiving Thiotepa medac?
Contraindications
Thiotepa medac must not be administered in the following situations. Your transplant team will thoroughly review your medical history before treatment to confirm none of these contraindications apply:
- Hypersensitivity: Do not use if you have a known allergy to thiotepa or to any of the excipients of the preparation.
- Pregnancy: Thiotepa is mutagenic, genotoxic and teratogenic. It must not be used during pregnancy. A pregnancy test is required before starting treatment in all women of childbearing potential.
- Breastfeeding: It is unknown whether thiotepa is excreted into breast milk, but given the serious toxicity, breastfeeding is contraindicated during and for an extended period after treatment.
- Yellow fever and other live vaccines: Concurrent use with yellow fever vaccine is contraindicated, and use with any live attenuated vaccine is strongly discouraged because of the risk of disseminated, potentially fatal vaccine-strain infection in the profoundly immunosuppressed patient.
Warnings and Precautions
Thiotepa medac always causes severe myelosuppression with near-complete loss of neutrophils, platelets, and red blood cells over several weeks. This is the intended effect in transplant conditioning, but it creates a period of profound vulnerability to life-threatening bacterial, fungal, and viral infections and severe bleeding. Treatment must be carried out in isolation rooms in specialized transplant units with continuous hematological monitoring, transfusion support, antimicrobial prophylaxis, and stem cell rescue. Signs such as fever, chills, sore throat, cough, rash, mouth ulcers, unusual bruising, dark urine, or shortness of breath must be reported to the medical team immediately.
In addition to bone marrow suppression, Thiotepa medac carries a number of other important safety considerations. Tell your transplant team before treatment if any of the following apply:
- Liver disease: Thiotepa is extensively metabolized in the liver, and hepatic impairment may increase exposure and toxicity. High-dose thiotepa also increases the risk of hepatic veno-occlusive disease (VOD/SOS, sinusoidal obstruction syndrome), a potentially fatal complication of HSCT conditioning in which the small hepatic veins become obstructed. Risk factors include pre-existing liver disease, prior hepatotoxic chemotherapy (especially gemtuzumab or inotuzumab), prior liver radiation, iron overload, and combination with busulfan.
- Kidney disease: Thiotepa metabolites are excreted renally; dose adjustment or close monitoring may be required. High doses may also contribute to renal tubular injury.
- Heart disease: Cardiotoxicity, including arrhythmias, congestive heart failure and (with cyclophosphamide-containing combinations) hemorrhagic myocarditis, has been reported. Baseline cardiac evaluation with ECG and echocardiogram is mandatory.
- Lung disease: Pulmonary toxicity including interstitial pneumonitis, idiopathic pneumonia syndrome, and acute respiratory distress may occur during and after treatment, especially in combination with busulfan or total body irradiation.
- Nervous system disease: At high doses thiotepa can cause confusion, somnolence, seizures and, rarely, encephalopathy or leukoencephalopathy. Tell your team about any history of seizures or neurological disease.
- Epilepsy medications: Phenytoin and fosphenytoin levels may be altered by chemotherapy; if you take antiepileptic drugs, levels should be monitored.
- Previous radiotherapy or chemotherapy: Prior CNS radiation increases the risk of leukoencephalopathy; cumulative anthracycline exposure increases cardiac risk; prior bleomycin increases the risk of lung toxicity.
VOD/SOS typically develops within the first 3 weeks after transplant and presents with weight gain, fluid retention, right upper quadrant pain, tender hepatomegaly, and rapidly rising bilirubin. Severe VOD has a high mortality rate and requires urgent intervention with defibrotide. Your team will monitor your liver tests, weight and fluid balance daily.
Skin Reactions and Skin Discoloration
High-dose thiotepa can cause a characteristic dusky, reddish-brown to bronze discoloration of the skin, particularly in intertriginous areas (skin folds, groin, axillae, under the breasts) and areas of occlusion (such as under ECG electrodes, adhesive tape, or tight clothing). This occurs because thiotepa and its metabolites are excreted in sweat and become concentrated where skin surfaces touch. The phenomenon is sometimes called “thiotepa burn” and can progress to painful erythema, blistering, and desquamation if not prevented. Frequent (3–4 times daily) bathing or showering with mild unscented soap and water during and for 48 hours after each thiotepa infusion, along with careful drying of skin folds and avoidance of occlusive dressings, substantially reduces the severity of these reactions.
Pregnancy, Breastfeeding, and Fertility
Thiotepa is a potent mutagen, genotoxin, and teratogen in animal and human studies. It has been shown to cause fetal malformations and chromosomal damage in germline cells. Pregnancy must be strictly avoided during and for an extended period after treatment.
Women of childbearing potential must have a negative pregnancy test confirmed before treatment and must use highly effective contraception (e.g., hormonal contraception with barrier method, intrauterine device) during treatment and for at least 6 months after the last dose. Notify your doctor immediately if you believe you may be pregnant.
Men are advised to use effective contraception during treatment and for up to 1 year after the last dose, because of the risk of mutagenic effects on sperm.
Breastfeeding must be discontinued before starting treatment and for an extended period afterward. The drug is excreted in sweat and is likely to appear in breast milk.
Fertility: Thiotepa is likely to cause temporary or permanent infertility in both men and women. Ovarian failure, premature menopause, and azoospermia are well described following high-dose regimens. All patients of reproductive age should be offered counseling about fertility preservation before starting treatment – for men, sperm cryopreservation (sperm banking), and for women, oocyte or embryo cryopreservation and, in selected cases, ovarian tissue preservation.
Children and Adolescents
Thiotepa medac is used extensively in pediatric HSCT and solid tumor conditioning, including in neonates and infants. Dosing in children may be calculated based on body weight (mg/kg) rather than body surface area in young children (<12 kg) because of the disproportionate body surface area-to-weight ratio. Growth, endocrine function (thyroid, growth hormone, gonadal axis), neurocognitive development, and secondary cancer risk require long-term follow-up in all pediatric transplant survivors.
Elderly Patients
Clinical experience in patients older than 65 years is limited. Decisions to proceed with high-dose thiotepa in older patients require careful evaluation of organ function, comorbidities, and performance status. Reduced-intensity conditioning regimens may be preferable.
Driving and Operating Machinery
Thiotepa can cause fatigue, dizziness, blurred vision, confusion and, rarely, seizures. Patients should not drive or operate dangerous machinery during conditioning and the early post-transplant period until the treating team confirms that it is safe to resume these activities.
Risk of Secondary Malignancies
Like all alkylating agents, thiotepa can damage DNA in healthy cells, including hematopoietic stem cells, and is associated with an increased long-term risk of secondary malignancies – most notably therapy-related myelodysplastic syndrome (t-MDS) and therapy-related acute myeloid leukemia (t-AML), which typically develop 3–10 years after treatment. Solid tumors, including skin cancers and oral cavity cancers, may also occur with higher cumulative incidence in transplant survivors. Lifelong surveillance by a long-term follow-up team is recommended.
How Does Thiotepa medac Interact with Other Drugs?
The metabolism and clearance of thiotepa involve several mechanisms that create potential for clinically significant interactions with other drugs. The parent compound is converted to its main active metabolite TEPA (triethylenephosphoramide) primarily by CYP2B6, with additional contribution from CYP3A4. Both thiotepa and TEPA are cytotoxic, so changes in the balance of metabolism can alter efficacy and toxicity. Alkylating agents also share overlapping toxicities (bone marrow suppression, mucositis, infection risk, hepatotoxicity) with many other drugs used in transplant regimens.
During conditioning, patients typically receive several supportive drugs simultaneously – antifungals, antivirals, antibiotics, anticonvulsants used for seizure prophylaxis with busulfan, and antiemetics. Your transplant pharmacist will carefully review the entire medication list and adjust doses and timing as needed to minimize interactions. It is essential to disclose all prescription medicines, over-the-counter drugs, herbal remedies, and supplements, including vitamins and probiotics.
Major Interactions
| Interacting Drug or Group | Effect | Clinical Significance |
|---|---|---|
| Live attenuated vaccines (yellow fever, MMR, varicella, BCG, oral polio, oral typhoid, rotavirus, nasal influenza) | Risk of disseminated, potentially fatal vaccine-strain infection in severely immunocompromised patients | Yellow fever vaccine is contraindicated. All live vaccines should be avoided before, during, and for at least 6–24 months after HSCT, per EBMT recommendations. |
| Busulfan (in combination conditioning regimens) | Thiotepa may inhibit hepatic metabolism of busulfan via CYP-mediated pathways; combined risk of hepatic VOD/SOS and mucositis | Separation of doses by >24 hours and therapeutic drug monitoring of busulfan are commonly employed; both drugs are intentionally used together but require careful scheduling. |
| Cyclophosphamide | Both drugs are activated by CYP2B6; competitive metabolism may reduce cyclophosphamide activation and alter thiotepa/TEPA exposure | Recommended to separate thiotepa and cyclophosphamide doses; do not administer simultaneously. |
| Phenytoin, fosphenytoin, carbamazepine, phenobarbital (CYP inducers) | Increased conversion of thiotepa to TEPA, altering the ratio of parent drug to active metabolite; phenytoin levels themselves may fall during chemotherapy | Monitor antiepileptic drug levels; valproate or levetiracetam may be preferred if seizure prophylaxis is needed. |
| Rifampicin, rifabutin, St John’s wort (strong CYP3A4/CYP2B6 inducers) | Increased thiotepa metabolism, potentially reducing efficacy of parent drug | Avoid concomitant use during conditioning; review the full medication list for herbal products. |
| Succinylcholine (suxamethonium) | Thiotepa inhibits plasma pseudocholinesterase; prolonged neuromuscular blockade and apnea may occur if succinylcholine is used | Avoid succinylcholine in patients who have recently received thiotepa; inform anesthesia team before any surgery or intubation. |
Additional Interactions
| Interacting Drug or Group | Effect | Clinical Significance |
|---|---|---|
| Ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, erythromycin (CYP3A4 inhibitors) | May reduce conversion of thiotepa to TEPA; may alter parent drug and metabolite exposure | Commonly used antifungal prophylaxis; monitor for altered toxicity, consider timing around thiotepa administration. |
| Warfarin and other oral anticoagulants | Altered anticoagulant effect during severe thrombocytopenia and hepatic dysfunction | Oral anticoagulants are generally held during conditioning; alternative thromboprophylaxis is managed by the transplant team. |
| Other cytotoxic chemotherapy and total body irradiation | Additive myelosuppression, mucositis, and organ toxicity | These combinations are intentional in conditioning; doses are individualized. |
| Aspirin and other NSAIDs | Increased bleeding risk during thrombocytopenia; nephrotoxicity | Generally avoided during conditioning and early post-transplant period. |
| Nephrotoxic drugs (aminoglycosides, vancomycin, amphotericin, IV contrast) | Additive kidney injury, potentially altering drug clearance | Use with close renal monitoring; therapeutic drug monitoring for aminoglycosides/vancomycin. |
| Inactivated (killed) vaccines | Reduced immune response during severe immunosuppression | Not contraindicated but typically deferred until immune reconstitution; a revaccination schedule is initiated 6–12 months after HSCT. |
What Is the Correct Dosage of Thiotepa medac?
Thiotepa medac is always prepared and administered by trained healthcare professionals in a specialized hematology, oncology, or stem cell transplantation center. The powder for concentrate for solution for infusion (15 mg per vial) is reconstituted with 1.5 mL of water for injection and further diluted with sodium chloride 9 mg/mL (0.9%) solution before administration as an intravenous infusion, typically over 2 to 4 hours, through a central venous catheter. Because thiotepa is a sensitizing and cytotoxic substance, it must be handled using standard cytotoxic handling procedures (personal protective equipment, closed-system transfer devices).
The dose, schedule, and combination drugs are chosen according to the specific conditioning regimen and the underlying disease. Dose calculation is based on body surface area (BSA, m²) in adults and older children, and on actual body weight (mg/kg) in pediatric patients weighing less than 12 kg. Doses are never self-administered or taken at home. What follows are representative dosing ranges from EMA-approved labeling; individual protocols may vary.
Adults – Autologous HSCT for Hematological Disease
Adult Autologous HSCT Conditioning
Dose range: 125 mg/m² to 300 mg/m² body surface area per day, given as a single daily infusion OR divided into two infusions 12 hours apart, for 1 to 3 consecutive days.
Maximum total dose: Generally not exceeding 900 mg/m² across the conditioning period.
Schedule: Starts a defined number of days before stem cell reinfusion (day 0), in combination with other conditioning drugs.
Administration: 2- to 4-hour intravenous infusion through a central venous catheter.
Adults – Allogeneic HSCT for Hematological Disease
Adult Allogeneic HSCT Conditioning
Dose range: 185 mg/m² to 481 mg/m² body surface area per day as a single daily infusion, OR divided into two infusions 12 hours apart, for 1 to 3 consecutive days (depending on the specific regimen).
Maximum total dose: Generally not exceeding 555 mg/m² across the conditioning period.
Common regimens: TBF (thiotepa + busulfan + fludarabine), thiotepa + cyclophosphamide, or thiotepa + total body irradiation.
Administration: 2- to 4-hour intravenous infusion through a central venous catheter, with careful scheduling around other conditioning agents.
Adults – Autologous HSCT for Solid Tumors
Adult Solid Tumor HSCT Conditioning
Dose range: 120 mg/m² to 250 mg/m² body surface area per day as a single daily infusion, OR divided into two infusions 12 hours apart, for 1 to 5 consecutive days.
Maximum total dose: Generally not exceeding 800 mg/m² across the conditioning period.
Use: Typically in combination with carboplatin and/or etoposide for recurrent germ cell tumors, advanced breast cancer, and other sensitive solid tumors.
Children – Autologous and Allogeneic HSCT for Hematological Disease
Pediatric HSCT Conditioning for Hematological Disease
Autologous HSCT: 125 mg/m² to 250 mg/m² per day as a single infusion, OR divided into two infusions 12 hours apart, for 1 to 3 consecutive days. Maximum total dose typically 375 mg/m².
Allogeneic HSCT: 125 mg/m² to 250 mg/m² per day as a single infusion, OR divided into two infusions 12 hours apart, for 1 to 3 consecutive days. Maximum total dose typically 375 mg/m².
Young children (<12 kg): Doses are calculated on a per kilogram body weight basis rather than body surface area.
Common pediatric indications: Beta-thalassemia major, sickle cell disease, inherited immunodeficiencies, refractory acute leukemias, high-risk lymphomas.
Children – Autologous HSCT for Solid Tumors
Pediatric Solid Tumor HSCT Conditioning
Dose range: 150 mg/m² to 350 mg/m² per day as a single infusion, OR divided into two infusions 12 hours apart, for 1 to 3 consecutive days. Maximum total dose typically 1050 mg/m².
Common indications: High-risk neuroblastoma, medulloblastoma and other embryonal brain tumors, Ewing sarcoma, germ cell tumors, retinoblastoma.
Combinations: Frequently with melphalan, carboplatin, etoposide, cyclophosphamide, or busulfan depending on protocol.
Dose Adjustments in Special Populations
Decisions about dose modification are made individually by the transplant team based on organ function tests obtained before treatment. Areas that typically require attention include:
- Hepatic impairment: Thiotepa is not recommended in patients with severe hepatic dysfunction because of markedly increased risk of toxicity and VOD/SOS. Mild-to-moderate liver impairment requires caution.
- Renal impairment: Since thiotepa metabolites are renally excreted, significant renal impairment may increase exposure; formal dose-adjustment guidance is limited, and dosing is based on clinical judgment.
- Performance status: Patients with poor performance status or significant comorbidities may be considered for reduced-intensity rather than myeloablative conditioning.
- Elderly: Data in patients over 65 are limited; tolerance of high-dose thiotepa is generally poorer, and reduced-intensity regimens are often preferred.
Missed Dose
Because Thiotepa medac is administered exclusively in a hospital by a specialized transplant team, the risk of a missed dose is minimal. The entire conditioning regimen follows a strict day-by-day schedule anchored to the day of stem cell reinfusion (day 0). If a dose is delayed because of an acute medical issue (for example, unexpected infection or organ dysfunction), the transplant team will decide whether the schedule can be adjusted, postponed, or the protocol modified. Patients should never attempt to “make up” a missed dose on their own.
Overdose
There is no specific antidote for thiotepa overdose. Overdose produces very severe and prolonged bone marrow suppression, severe mucositis, hepatotoxicity, and multi-organ toxicity. Management is entirely supportive: intensive antimicrobial therapy, transfusion support (red cells, platelets, fresh frozen plasma as needed), meticulous care of mucositis, aggressive nutritional support (often parenteral), and – when possible – early stem cell rescue. Hemodialysis is not effective because of tissue binding. Because Thiotepa medac is administered only by trained professionals in a controlled hospital setting using double-checked dose calculations, accidental overdose is exceedingly rare.
How Thiotepa medac Is Prepared and Administered
Thiotepa medac is supplied as a sterile, white crystalline powder in glass vials containing 15 mg of thiotepa. Before use, the powder is reconstituted with 1.5 mL of water for injection without preservative to produce a 10 mg/mL solution. The required dose is then withdrawn and further diluted in 500 mL of sodium chloride 9 mg/mL (0.9%) solution for infusion (smaller volumes may be used in pediatric patients with fluid restrictions). The final solution must be clear and colorless; any solution that is cloudy, contains precipitate, or shows crystallization should be discarded.
The infusion is given over 2 to 4 hours through a central venous catheter, using an in-line filter if stipulated by local protocols. Reconstituted and diluted solutions should be administered within 8 hours if stored at 2–8°C. The drug must not be mixed in the same infusion bag or line with other drugs. Thiotepa is excreted in sweat; patients should bathe frequently (3–4 times daily) with water only during and for 48 hours after each dose, and linens should be changed daily to minimize skin toxicity and protect caregivers.
Thiotepa medac is a cytotoxic chemotherapy drug and vesicant. It must always be prepared and administered by trained healthcare professionals in a specialized hospital transplant or oncology unit. Strict safety precautions are required during preparation and handling, including personal protective equipment and closed-system transfer devices. It is never self-administered at home. Pregnant healthcare workers should not handle the product.
What Are the Side Effects of Thiotepa medac?
Side effects of Thiotepa medac reflect both the drug’s mechanism (alkylation damage to rapidly dividing cells, including bone marrow, skin, mucosa, hair follicles and gonads) and the fact that it is almost always used at myeloablative doses with additional chemotherapy and sometimes total body irradiation. Because side effects are expected rather than rare, the entire conditioning and post-transplant period is designed around prevention, early detection, and intensive supportive care. The frequency categories below are adapted from the European SmPC for thiotepa-containing products and from published HSCT experience.
Patients and families should understand that “very common” effects are nearly universal at transplant doses, while “rare” or “very rare” effects may still be serious and require urgent attention. Any new symptom during and after treatment should be reported immediately to the transplant team.
Very Common
May affect more than 1 in 10 people
- Profound reduction in neutrophils (neutropenia), white cells (leukopenia), and all blood cell lines (pancytopenia)
- Anemia (low red blood cell count)
- Thrombocytopenia (low platelet count) with increased bleeding risk
- Bacterial, viral, and fungal infections, including bloodstream infections (sepsis)
- Reactivation of cytomegalovirus (CMV), Epstein-Barr virus (EBV), varicella-zoster, or herpes simplex
- Fever, chills, general malaise
- Severe oral and gastrointestinal mucositis (mouth sores, esophagitis, enteritis)
- Nausea, vomiting, diarrhea, abdominal pain
- Loss of appetite (anorexia), weight loss
- Hair loss (alopecia) – nearly universal
- Skin redness (erythema), rash
- Reddish-brown to bronze skin discoloration, particularly in skin folds and areas of occlusion (characteristic of high-dose thiotepa)
- Itching (pruritus) and dry skin
- Fatigue, weakness (asthenia)
- Headache, dizziness
- Elevated liver function tests (AST, ALT, alkaline phosphatase, bilirubin)
- Acute graft-versus-host disease (in allogeneic transplant, attributable to the overall regimen)
- Electrolyte disturbances (low potassium, low magnesium, low calcium, low albumin)
- Increased blood urea
- Edema, weight gain from fluid retention
- Anxiety, confusion, insomnia
- Transient azoospermia or amenorrhea (often permanent with high-dose conditioning)
Common
May affect up to 1 in 10 people
- Hemorrhagic cystitis (especially in combination with cyclophosphamide)
- Hematuria (blood in the urine)
- Acute kidney injury, elevated creatinine
- Hepatic veno-occlusive disease / sinusoidal obstruction syndrome (VOD/SOS)
- Increased transaminases with hepatic dysfunction
- Hypertension or hypotension, tachycardia
- Cardiac arrhythmia, heart failure
- Pericardial effusion
- Cough, shortness of breath (dyspnea), hypoxia
- Pneumonia and other chest infections
- Blister formation and skin peeling (desquamation)
- Nail changes
- Seizures (particularly at the higher end of the dose range)
- Peripheral neuropathy, paresthesias
- Blurred vision, conjunctivitis
- Hyperglycemia
- Electrolyte shift including hyponatremia and hyperphosphatemia
- Gastrointestinal bleeding
- Back pain, joint pain, muscle pain
- Chest pain
Uncommon
May affect up to 1 in 100 people
- Interstitial pneumonitis, idiopathic pneumonia syndrome, pulmonary edema
- Pulmonary hemorrhage
- Acute respiratory distress syndrome (ARDS)
- Encephalopathy, leukoencephalopathy, confusion, altered mental status
- Cerebrovascular events, ischemic or hemorrhagic stroke
- Acute liver failure
- Posterior reversible encephalopathy syndrome (PRES)
- Thrombotic microangiopathy, transplant-associated TMA
- Myocardial infarction, cardiac tamponade
- Aspergillosis and other invasive fungal disease
- Reactivation of adenovirus, BK virus, or human herpesvirus 6
- Hepatitis B or C reactivation in carriers
- Severe hypersensitivity reactions, anaphylaxis
- Delirium, hallucinations
- Polyneuropathy
- Hearing loss, tinnitus
Rare
May affect up to 1 in 1,000 people
- Severe cutaneous reactions (erythema multiforme)
- Pericarditis
- Graft failure or rejection (allogeneic HSCT)
- Optic neuritis or retinal toxicity
- Severe hepatorenal syndrome
- Severe coagulopathy including disseminated intravascular coagulation (DIC)
Very Rare
May affect up to 1 in 10,000 people
- Stevens-Johnson syndrome and toxic epidermal necrolysis (life-threatening skin and mucous membrane reactions)
- Progressive multifocal leukoencephalopathy (PML) related to profound immunosuppression
Not Known
Frequency cannot be estimated from available data
- Therapy-related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML), typically 3–10 years after treatment
- Secondary solid tumors (skin cancers, oral cavity cancers and others) with long follow-up
- Long-term endocrine effects: hypothyroidism, growth hormone deficiency, premature ovarian insufficiency
- Chronic graft-versus-host disease (allogeneic HSCT)
- Pulmonary fibrosis with long follow-up
- Cataracts and other late ocular complications
It is important to report any suspected side effects to your healthcare provider, even those not listed here. Reporting helps regulatory authorities continuously monitor the benefit-risk balance of medicines. You can also report side effects directly to your national pharmacovigilance agency (for example, the FDA MedWatch program in the United States, the Yellow Card scheme in the United Kingdom, or the EudraVigilance system of the European Medicines Agency).
How Should Thiotepa medac Be Stored?
Proper storage of Thiotepa medac is essential to maintain the stability and safety of the preparation. As a hospital-administered cytotoxic medication, storage is managed by pharmacy and nursing staff following national and institutional cytotoxic drug handling protocols. Patients do not handle the drug themselves, but understanding the storage requirements may be useful for family members and caregivers.
- Unopened vials: Store in a refrigerator at 2–8°C (36–46°F) in the original outer carton to protect from light. Do not freeze.
- After reconstitution (in the vial): The reconstituted solution (10 mg/mL) should be used immediately. If not used immediately, it may be stored at 2–8°C for up to 8 hours.
- After dilution (in the infusion bag): The diluted solution for infusion should preferably be used immediately. In-use chemical and physical stability has been demonstrated for up to 8 hours at 2–8°C.
- Total combined in-use time: From reconstitution through to end of infusion, the combined time should not exceed 8 hours, including the infusion duration.
- Expiry date: Do not use Thiotepa medac after the expiry date printed on the carton and vial (EXP). The expiry date refers to the last day of the stated month.
- Keep out of reach of children.
Any unused product or waste material must be disposed of in accordance with local regulations for cytotoxic drugs. Disposal is managed by the healthcare team using cytotoxic waste procedures to protect pharmacy, nursing, cleaning, and waste handling staff.
What Does Thiotepa medac Contain?
Understanding the composition of Thiotepa medac is useful for identifying potential allergens and understanding how the drug is prepared before administration.
- Active substance: Thiotepa. Each vial contains 15 mg of thiotepa.
- After reconstitution: Each mL of reconstituted solution contains 10 mg of thiotepa (1.5 mL of water for injection is added to each 15 mg vial).
- Other excipients: None (depending on the specific marketing presentation, the product may be supplied as pure lyophilized thiotepa powder without additional excipients).
Appearance: Thiotepa medac is a white to off-white crystalline powder supplied in a clear glass vial. After reconstitution, the solution should be clear and colorless. Discard any solution that is cloudy, discolored, or contains visible particles.
Pack size: Thiotepa medac is available in packs containing 1 or 10 vials of 15 mg thiotepa.
Marketing authorization holder: medac Gesellschaft für klinische Spezialpräparate mbH, Theaterstrasse 6, 22880 Wedel, Germany.
Related Thiotepa Products and Other Brand Names
Thiotepa is available internationally under several brand names, including Tepadina (originator, authorized by Adienne SA, available in 15 mg and 100 mg vials across Europe and North America), Thiotepa medac (medac GmbH, 15 mg vials), and various generic presentations. All thiotepa products contain the same active substance and share the same clinical indications, but differ in manufacturing details, pack sizes, and reconstitution instructions. Always follow the specific Summary of Product Characteristics or prescribing information for the product actually dispensed.
Frequently Asked Questions About Thiotepa medac
Yes and no. All thiotepa-containing products contain the same active substance (thiotepa) and are used for the same clinical indications, with the same mechanism of action. Thiotepa medac (made by medac GmbH, Germany) and Tepadina (originator, made by Adienne SA) are therapeutically interchangeable when dosed correctly. However, they differ in strength options (Thiotepa medac is available as 15 mg vials; Tepadina comes in both 15 mg and 100 mg vials), in pack configuration, and in some reconstitution details. Your hospital pharmacy will dispense whichever product is available locally and will calculate your dose using the specific product monograph.
Thiotepa is a sulfur-containing compound, and as it is metabolized, small volatile sulfur-containing molecules are released in the breath, sweat, and urine. Patients, family members, and staff often notice a characteristic sulfurous, garlic-like, or “cooked cabbage” odor during treatment and for a day or two afterward. This is expected and harmless to others, but because thiotepa and its metabolites are excreted in sweat, it is important to bathe frequently with water only (3 to 4 times daily) during and for 48 hours after each infusion to prevent skin irritation and reddish-brown discoloration in skin folds. Bed linens and clothing should be changed daily.
Hair loss (alopecia) is nearly universal with high-dose thiotepa used in transplant conditioning. It usually begins 2 to 3 weeks after the start of conditioning and is typically complete, affecting scalp, eyebrows, eyelashes, and body hair. Regrowth begins 2 to 3 months after chemotherapy ends in most patients, although the first new hair may initially be finer or of a slightly different color or texture than before. Scalp cooling (cold cap therapy) is not effective with high-dose thiotepa conditioning and is not recommended in this setting. Your transplant team can discuss wigs, hats, scarves, and practical skin and scalp care during the hair-loss phase.
Yes, most likely. High-dose thiotepa, particularly in combination with other alkylating agents such as busulfan or cyclophosphamide, commonly causes temporary or permanent infertility. In women, this may mean loss of ovarian function and premature menopause, especially in those over 30 years of age. In men, azoospermia (absence of sperm) is common and may be permanent. Because of this, fertility preservation should be discussed before starting treatment. For men, sperm banking is straightforward and widely available. For women, options include oocyte (egg) or embryo cryopreservation and, in some centers, ovarian tissue cryopreservation. Pediatric patients should be referred to specialist fertility preservation programs appropriate for their age. Your transplant team will involve fertility specialists as part of pre-transplant planning whenever time allows.
The exact duration depends on the type of transplant, the conditioning regimen used, and how smoothly you recover. In most centers, patients stay in hospital for 3 to 6 weeks for autologous transplants and 4 to 8 weeks for allogeneic transplants. You will typically be in an isolation room with filtered air during the period of severe neutropenia. You will be discharged only when blood counts have begun to recover, you are able to eat and drink adequately, infections and mucositis are controlled, and you are safe to continue outpatient follow-up. Close outpatient monitoring continues for many months – typically 100 days intensively, then for at least one year, and long-term thereafter.
Alkylating agents, including thiotepa, can damage DNA in normal cells as well as cancer cells. In a minority of patients, this leads to therapy-related myelodysplastic syndrome (t-MDS) or therapy-related acute myeloid leukemia (t-AML), typically 3 to 10 years after treatment, as well as an increased long-term risk of solid tumors (particularly of the skin, oral cavity, and thyroid). The absolute risk varies by regimen, age at transplant, and other cancer treatments received, but is generally in the range of a few percent over 10–20 years. This risk is real but is almost always outweighed by the benefit of controlling the primary disease. Long-term follow-up clinics with regular health surveillance (blood counts, skin checks, dental reviews, cancer screening) are essential for all transplant survivors.
Yes. Previous vaccine-induced immunity is largely lost after HSCT conditioning with thiotepa-based regimens, so a complete revaccination program is standard care. Inactivated vaccines (for example tetanus, diphtheria, pertussis, inactivated polio, Haemophilus influenzae type b, pneumococcal conjugate, meningococcal, inactivated influenza, hepatitis B, HPV, and COVID-19) are typically started 6 months after transplant. Live attenuated vaccines (for example MMR, varicella, yellow fever) are contraindicated during active immunosuppression and are usually deferred to at least 24 months after transplant, and only if the patient is off immunosuppressive therapy and has adequate immune reconstitution. Your transplant center will provide an individualized revaccination schedule following EBMT or ASTCT guidelines.
References
- European Medicines Agency (EMA). Tepadina (thiotepa) – Summary of Product Characteristics (SmPC). Last updated 2025. Available at: ema.europa.eu/en/medicines/human/EPAR/tepadina
- U.S. Food and Drug Administration (FDA). Tepadina (thiotepa) for injection – Prescribing Information. Last updated 2024.
- Sureda A, Bader P, Cesaro S, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplantation. 2015;50(8):1037-1056. doi:10.1038/bmt.2015.6
- Ferreri AJM, Cwynarski K, Pulczynski E, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial (IELSG32). The Lancet Haematology. 2017;4(11):e510-e523. doi:10.1016/S2352-3026(17)30174-6
- Sauter CS, Matasar MJ, Meikle J, et al. Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. Blood. 2015;125(16):2579-2581. doi:10.1182/blood-2014-10-606939
- Lazarus HM, Reed MD, Spitzer TR, et al. High-dose i.v. thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer. Cancer Treatment Reports. 1987;71(7-8):689-695.
- European Society for Blood and Marrow Transplantation (EBMT). The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies. 8th Edition. Springer; 2024.
- Carreras E, Dufour C, Mohty M, Kröger N (eds). The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th Edition. Springer Open; 2019. Available at: link.springer.com/book/10.1007/978-3-030-02278-5
- Mohty M, Dalle JH, Corbacioglu S, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation. 2016;51(7):906-912. doi:10.1038/bmt.2016.130
- Cordelli DM, Masetti R, Zama D, et al. Etiology, characteristics and outcome of seizures after pediatric hematopoietic stem cell transplantation. Seizure. 2014;23(2):140-145. doi:10.1016/j.seizure.2013.10.006
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023. Geneva: World Health Organization.
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Hematopoietic Cell Transplantation, B-Cell Lymphomas, Central Nervous System Cancers, Multiple Myeloma. Versions 2024–2025.
- Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation. 2012;18(3):348-371. doi:10.1016/j.bbmt.2011.12.519
Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in Hematology, Oncology, and Clinical Pharmacology
Medical Review
iMedic Medical Review Board – Independent panel following EMA, FDA, EBMT, and WHO guidelines
Evidence Level
Level 1A – Based on systematic reviews, meta-analyses, and randomized controlled trials
Last Reviewed
– Updated according to current EMA SmPC and FDA prescribing information
All medical content on iMedic is written and reviewed by qualified healthcare professionals following the GRADE evidence framework. We adhere to strict editorial standards with no commercial funding or pharmaceutical sponsorship. For questions or corrections, please contact our editorial team.